Real-world treatment and long-term outcomes after autologous stem cell transplantation in first line for myeloma in France and Algeria before the daratumumab era

Émilie Martin; Stéphane Morisset; Mohamad Sobh; Alfred Quillon; Hélène Boyer; Philippe Rey; Emmanuelle Nicolas Virelizier; Souad Assaad; Amine Belhabri; Haïfa Bahri; Laure Lebras; Valérie Mialou; Jean-Paul Bourgeot; M Teyssier; Mohamed Amine Brahimi; Soufi Osmani; Kamila Amani; Samira Bouchama; Lila Charef; Nabil Yafour; Badra Entasoltan; Anne Sophie Michallet; Mohamed-Amine Bekadja; Mauricette Michallet

doi:10.1016/j.retram.2026.103566

Key Points

Long-term outcomes showed a notable durability of response in myeloma patients treated with autologous stem cell transplantation.
Survival rates demonstrated a 5-year overall survival of approximately 50% in patients undergoing this treatment.
Observational analysis across two countries highlighted differences in treatment pathways and outcomes before the daratumumab era.
Findings may guide future treatment decisions and clinical approaches in myeloma care, stressing the importance of ongoing analysis.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Observational analysis reports long-term outcomes in myeloma patients treated with autologous stem cell transplantation, suggesting significant implications for future therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Martin et al. (2026) studied this question.

synapsesocial.com/papers/69a75d72c6e9836116a277ef https://doi.org/10.1016/j.retram.2026.103566

View at Publisher

Ask AI

Bookmark

Share

Real-world treatment and long-term outcomes after autologous stem cell transplantation in first line for myeloma in France and Algeria before the daratumumab era

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Real-world treatment and long-term outcomes after autologous stem cell transplantation in first line for myeloma in France and Algeria before the daratumumab era

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

More related papers

More from Current Research in Translational Medicine

Keep reading

More related papers

More from Current Research in Translational Medicine